secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2022-06-29T23:59:59+00:00
Accession:  0001193125-22-184488
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron stops NSCLC trial enrollment after interim data; revises breast cancer trial
--------------------------------------------------------------------------------

- Interim data from 20 patients: ALRN-6924 patients completed 93% of first 4 chemo cycles vs 78% placebo.
- Progression-free survival median 4.6 months on ALRN-6924 vs 3.2 months on placebo.
- Composite primary endpoint: 56% cycles free of Grade ≥3 hematologic toxicities vs 50% placebo.
- Plans to stop further NSCLC enrollment; apply learnings to breast cancer trial with revised dosing and endpoint.
- Will not further enroll 0.3 mg/kg and 0.6 mg/kg cohorts in breast cancer trial; higher dose to be evaluated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522184488/0001193125-22-184488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522184488/d314855d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-184488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer